Stocks
SAB Biotherapeutics, Inc.SABS
NASDAQHealthcareBiotechnology$2.84
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing transchromosomic bovine-derived polyclonal antibodies for infectious diseases and other conditions. Its lead candidates target COVID-19 and other respiratory infections, with a platform that may offer advantages in speed and breadth over traditional monoclonal antibodies. Investors track SABS for its novel production technology and upcoming clinical data readouts.
52W Range: $2.44-$5.15
Congressional Interest in SAB Biotherapeutics, Inc. (SABS)
No congressional trades have been disclosed for SAB Biotherapeutics, Inc. (SABS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading SABS?
No congressional trades found for this stock.